Severe Respiratory Diseases
Zambon is continually searching for solutions, which will make patients’ lives better for those affected by severe respiratory diseases such as CF, BOS and NCFB.
Around 100,000 people worldwide suffer from Cystic Fibrosis, the most common severe genetic disease. This multi-organ disease mainly affects the lungs, which are hit by chronic infections and inflammations that cause their progressive deterioration.
*Sources: ECFS Patient Registry, Report 2015
New cases of Cystic Fibrosis every year in Italy
Cases of Cystic Fibrosis affecting children in Europe
We want to develop treatments that play a key role in treating Cystic Fibrosis, as well as in managing severe respiratory diseases
Bronchiolitis Obliterans Syndrome (BOS)
BOS is a rapidly progressive disease that usually leads to respiratory failure and death within two to four years after diagnosis*. BOS is caused by an inflammatory process triggered by the immune system that irreversibly destroys the airways of the lungs. BOS is commonly seen in patients following lung transplantation and allogeneic hematopoietic stem cell transplant, though it is also associated with autoimmune disease and exposure to environmental contaminants**.
*Chambers DC, et al. J Heart Lung Transplant. 2018; 37(10):1169–1183.
**Krishna R. Bronchiolitis Obliterans (StatPearls [Internet]. March 13, 2019
develop BOS by 10 years post lung transplantation
cause of death following first year post lung transplant
Zambon is supporting a global clinical development plan
Although lung transplant survival has become an established treatment option for end-stage lung stage, extended survival remains a challenge. There is currently no approved treatment for BOS*. Zambon is supporting a global clinical development plan to evaluate the safety and efficacy of using investigational liposomal cyclosporine A for inhalation formulation to treat BOS in patients after lung transplant and after allogeneic hematopoietic stem cell transplantation. The rationale of inhaled therapies is to deliver sufficient concentrations of the drug directly to the site of disease in the lungs while minimizing systemic exposure.
*Verleden GM, et al. J Heart Lung Transplant 2019; May; 38(5):493-503.
NCFB – Non Cystic Fibrosis Bronchiectasis
Bronchiectasis is a lung condition associated with chronic cough and sputum production that is rapidly increasing in prevalence in Europe. A common finding in bronchiectasis is persistent infection of the airways by bacterial pathogens, most notably P. aeruginosa, H. influenza, S. aureus and non-tuberculous mycobacteria (NTM) as well as fungi. Infection with P. aeruginosa is associated with worse outcomes including more frequent exacerbations, worse quality of life and elevated mortality. Recommended therapies for people with bronchiectasis primarily target the consequences of bronchiectasis, such as airway obstruction and infection, but not all therapies have equally established evidence of efficacy, nor will all patients benefit from all of these therapies.
*Michal Shteinberg, Patrick A. Flume, James D. Chalmers. Is bronchiectasis really a disease? Eur Respir Rev 2020; 29: 190051
*James D. Chalmers et al. Cross-infection risk in patients with bronchiectasis: a position statement from the European Bronchiectasis Network (EMBARC), EMBARC/ELF patient advisory group and European Reference Network (ERN-Lung) Bronchiectasis Network. Eur Respir J 2018; 51: 1701937
of patients with bronchiectasis have a chronic infection
patients involved in Promis 1 and Promis 2 clinical trials
We are at the forefront for development of a treatment
With our Phase III study on NCFB - Non Cystic Fibrosis Bronchiectasis we are at the forefront for development of a treatment against this disease. Our aim is to offer new perspectives for patients suffering from NCFB, a seriously invalidating disease